Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Senzime Temettü

Temettü kriter kontrolleri 0/6

Senzime şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.5%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-SEK 1.09
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

Feb 16

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

Jan 19

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Dec 23

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Nov 26

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SEZI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SEZI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Senzime Piyasaya Karşı Temettü Getirisi

SEZI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SEZI)	n/a
Pazarın Alt %25'i (SE)	1.5%
Pazarın En İyi %25'i (SE)	4.3%
Sektör Ortalaması (Medical Equipment)	1.5%
Analist tahmini (SEZI) (3 yıla kadar)	n/a

Önemli Temettü: SEZI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SEZI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SEZI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SEZI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Senzime Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Second quarter 2024 earnings: Revenues miss analyst expectations

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

New minor risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Chief Financial Officer recently bought kr67k worth of stock

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

New major risk - Financial position

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Independent Chairman recently bought kr740k worth of stock

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Less than half of directors are independent

Senzime AB (publ) Provides Earnings Guidance for 2025

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Consensus revenue estimates fall by 34%

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to kr34.00

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Will Senzime (STO:SEZI) Spend Its Cash Wisely?

Price target decreased to kr34.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

New 90-day low: kr21.50

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

New 90-day high: kr25.80

Senzime AB (publ) Gets US Patent for OnZurf Probe

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Senzime Lands New Order from South Korea of SEK 1 Million

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Third quarter 2020 earnings released: kr0.20 loss per share

Senzime AB (publ) Announces Nomination Committee for 2021 Annual General Meeting

Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.A

Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical Company

New 90-day low: kr19.70

Senzime AB (Publ) Announces Management Changes

Senzime AB (publ) Receives Order from Switzerland

New 90-day high: kr26.30

Earnings released